PLUS THERAPEUTICS, INC.

Plus Therapeutics is a U.S. healthcare company that develops and sells precise diagnostic tools and targeted radiopharmaceuticals for cancers affecting the central nervous system (CNS). Its wholly owned subsidiary, CNSide Diagnostics, LLC, develops and sells specialized laboratory tests, including CNSide®, which are designed to detect tumor cells that have spread to the central nervous system in patients with carcinomas and melanomas. In radiopharmaceuticals, the company's primary candidate, rhenium (186Re) obisbemeda, is specifically developed for CNS cancers such as recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC). This treatment is delivered directly and locally using approved standard methods for tissue access, such as convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Additionally, the acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat various solid organ cancers, including primary and secondary liver cancers, through intra-arterial injection. The company's new radioactive drug formulations, medical devices, and therapeutic candidates aim to overcome the limitations of traditional radiation therapy, such as long treatment durations, damage to healthy cells, and insufficient radiation doses. These products are designed to deliver safe and effective radiation doses directly to tumors, potentially in a single treatment. This is achieved through innovative drug formulations, including encapsulating radionuclides like rhenium isotopes within nanoliposomes and microspheres. These formulations are intended to increase patient-absorbed radiation doses and extend retention times, ensuring that the isotope clears after significant and essentially complete radiation decay, which is expected to result in less exposure to normal tissue/organs and improved safety margins.